PE20170305A1 - Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio - Google Patents

Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio

Info

Publication number
PE20170305A1
PE20170305A1 PE2016002763A PE2016002763A PE20170305A1 PE 20170305 A1 PE20170305 A1 PE 20170305A1 PE 2016002763 A PE2016002763 A PE 2016002763A PE 2016002763 A PE2016002763 A PE 2016002763A PE 20170305 A1 PE20170305 A1 PE 20170305A1
Authority
PE
Peru
Prior art keywords
paracetamol
celecoxib
treatment
inflammatory pain
synergistic combination
Prior art date
Application number
PE2016002763A
Other languages
English (en)
Inventor
Medellin Jorge Fernando Cantu
Original Assignee
More Pharma Corp S De R L De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52279400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by More Pharma Corp S De R L De C V filed Critical More Pharma Corp S De R L De C V
Publication of PE20170305A1 publication Critical patent/PE20170305A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a una combinacion farmaceutica sinergistica util para el tratamiento de dolor inflamatorio, caracterizada porque comprende entre 375 mg y 500 mg de paracetamol y entre 50 mg y 75 mg de celecoxib. Tambien se refiere a una composicion farmaceutica que lo comprende
PE2016002763A 2013-07-11 2014-07-11 Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio PE20170305A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/055710 WO2015004505A1 (es) 2013-07-11 2013-07-11 Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio

Publications (1)

Publication Number Publication Date
PE20170305A1 true PE20170305A1 (es) 2017-04-21

Family

ID=52279400

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016000043A PE20160239A1 (es) 2013-07-11 2014-07-11 Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
PE2016002763A PE20170305A1 (es) 2013-07-11 2014-07-11 Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016000043A PE20160239A1 (es) 2013-07-11 2014-07-11 Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio

Country Status (8)

Country Link
CL (1) CL2015003211A1 (es)
CR (1) CR20160021A (es)
CU (1) CU24440B1 (es)
DO (1) DOP2016000008A (es)
EC (1) ECSP16005679A (es)
MX (1) MX366118B (es)
PE (2) PE20160239A1 (es)
WO (2) WO2015004505A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package
PE20251234A1 (es) * 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V Combinacion de celecoxib - acetaminofen de estabilidad mejorada y procedimiento para su preparacion
PE20251233A1 (es) 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V Tableta multiactivos en el tratamiento y control de dolor severo cronico y metodo de preparacion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070251A1 (en) * 2002-02-19 2003-08-28 Adcock Ingram Limited Pharmaceutical combinations of cox-2 inhibitors and opiates
GB0423103D0 (en) * 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents

Also Published As

Publication number Publication date
CU24440B1 (es) 2019-09-04
MX2015013911A (es) 2015-12-08
CL2015003211A1 (es) 2016-04-29
WO2015004634A3 (es) 2015-04-09
CU20160002A7 (es) 2016-06-29
WO2015004634A2 (es) 2015-01-15
PE20160239A1 (es) 2016-05-13
MX366118B (es) 2019-06-27
WO2015004505A1 (es) 2015-01-15
DOP2016000008A (es) 2016-03-15
ECSP16005679A (es) 2017-08-31
CR20160021A (es) 2016-04-08

Similar Documents

Publication Publication Date Title
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MY196173A (en) Cot Modulators And Methods Of Use Thereof
MX378273B (es) Compuestos activos hacia bromodominios.
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CL2016001547A1 (es) Composiciones para el cuidado oral
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
GT201700138A (es) Pirazolpiridinaminas
WO2014153009A3 (en) Thiosaccharide mucolytic agents
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
CL2016001350A1 (es) Composiciones de ketoprofeno de accion prologanda.
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
CL2015002188A1 (es) Agentes analgésicos oculares tópicos
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
MX2017008879A (es) Composicion farmaceutica para el tratamiento de la micosis.
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol